Dr. Reddy’s Laboratories has launched Bupropion HCI extended-release tablets, USP (SR) in 100 mg, 150 mg and 200 mg, a therapeutic equivalent generic version of Wellbutrin SR (bupropion HCI) Sustained-Release Tablets in the United States market approved by the US Food & Drug Administration (USFDA). Dr. Reddy’s Buproprion SR tablets are available in 100 mg, 150 mg and 200 mg, in bottle count sizes of 60, 100 and 500.
Wellbutrin SR is a registered trademark of the GSK group of companies. The Wellbutrin SR brand and generic had US sales of approximately $109.6 million MAT for the most recent twelve months ending in July 2016, according to IMS Health.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It is committed to provide affordable and innovative medicines for healthier lives. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
